Information Provided By: 
Fly News Breaks for December 8, 2015
EGRX
Dec 8, 2015 | 15:18 EDT
William Blair analyst Tim Lugo raised Eagle Pharmaceuticals' (EGRX) price target to $109 from $100 on shares following the approval of Bendeka. Lugo believes that today's approval de-risks Eagle's largest value driver as Teva (TEVA) anticipates making Bendeka commercially available to patients in the first quarter of 2016 with the company noting their intention to switch a majority of patients from their current product Treanda. The analyst rates Eagle shares an Outperform.
News For EGRX From the Last 2 Days
There are no results for your query EGRX
